Table 5 Clinicopathological features of ENKTL of different primary sites
Characteristics | Breast*, n (%) | Nasal, n (%) [23] | GI tract, n (%) [24] | Skin, n (%) [25] | Testis, n (%) [14] | Larynx, n (%) [13] |
|---|---|---|---|---|---|---|
Number of cases | 7 | 92 | 55 | 16 | 21 | 31 |
Median age (range) (year) | 40 (20–54) | 52 (21–89) | 39 (14–75) | 32 (16–72) | 44 (21–79) | 50 (13–77) |
B symptoms | 5 (100) | 36 (39) | 19 (35) | 11 (69) | 7 (33) | 10 (32) |
Ulceration | 0 (0) | NR | 55 (100) | 7 (44) | NR | 12 (39) |
Concomitant diseases | 5 (100) | NR | NR | NR | NR | NR |
Pleomorphic | 5 (83) | NR | 42 (76) | 13 (81) | NR | 8 (26) |
Number of CD30 + cases | 4 (67) | 36 (39) | 13 (41) | 2 (15) | 5 (31) | NR |
Median CD30 expression, % (range) | 62.5 (50–80) | NR | NR | NR | NR | NR |
Median Ki-67 index, % (range) | 80 (70–95) | NR | 70 (50–90) | 60 (NR) | 80 (50–90) | 60 (30–80) |
TR gene rearrangement (monoclonal/polyclonal) | 3 (60) | 35 (38) | 9 (53) | 0 (0) | NR | 1 (17) |
Median survival (range) (month) | 5 (1–9) | 19.2 (NR) | 14 (1–56) | 7 (2–20) | 15.3 (0.5–87) | 9 (1–104) |